Conversely, ACSL5 knockdown reduces food intake by increasing glucagon-like peptide (GLP) and peptide YY (PYY) secretion and decreasing gastric emptying rate, mitigating HFD-induced obesity and insulin resistance [96]. Here, ACSL5 is linked to obesity due to melanocortin 4 receptor deficiency.